CLINICAL CORE

临床核心的首要目标是表征行为，认知，运动，神经影像学， ADRC受试者的蛋白质组学和遗传学特征，以新颖的，多学科的方式，并促进招募 研究对象的正常和异常老化。临床核心的具体目标是：1）招募， 评估并纵向随访正常老年人（n=300）、轻度认知障碍患者 (MCI; n=150）、轻度AD（n=100）、额颞叶变性（FTLD; n=75）、HIV（n=50）、肌萎缩性 侧索硬化（ALS; n=20）、皮质基底节变性和进行性核上性麻痹（CBD/PSP; n=25）和克雅氏病（CJD; n=20），以及已知基因突变的家族成员 2）与教育核心合作，招募、评估和纵向跟踪 华裔美国人（n=100）和拉丁美洲人（n=50）患者和对照; 3）提供临床数据， 用于研究衰老和神经退行性疾病的特征化受试者;以及4）获得生物学 用于基因组和蛋白质组学研究的样本，以及贡献新的队列，包括华裔美国人 和FTLD患者，向国家AD细胞库（NCRAD）。所有受试者将使用 UDS加上几个神经，认知和个性的措施，具体到UCSF，以更好地了解 痴呆症之间的异质性和重叠，提高了我们捕捉痴呆症最早迹象的能力。 神经变性，研究从正常衰老到MCI的过渡，并促进干预。 相关性（参见说明）： 在美国，痴呆症的流行很快就会达到流行病的程度。通过 招募和评估广泛的患者和老年对照，该ADRC的临床核心发挥 在这个ADRC的能力，以促进干预，转化和生物学研究的核心作用， 开发新的治疗方法和优化患者护理所必需的。

The overarching goal of the Clinical Core is to characterize the behavioral, cognitive, motor, neuroimaging, proteomic and genetic features of ADRC subjects in novel, multidisciplinary ways, and facilitate enrollment of subjects in studies of normal and abnormal aging. The specific aims of the Clinical Core are to 1) Recruit, evaluate, and longitudinally follow cohorts of normal elderly (n=300), patients with mild cognitive impairment (MCI; n=150), mild AD (n=100), frontotemporal lobar degeneration (FTLD; n=75), HIV (n=50), amyotrophic lateral sclerosis (ALS; n=20), corticobasal degeneration and progressive supranuclear palsy (CBD/PSP; n=25), and Creutzfeldt-Jakob disease (CJD; n=20), and members of families with known mutations in genes that predispose them to FTLD; 2) Work with the Education Core to recruit, evaluate, and longitudinally follow Chinese-American (n=100) and Latino (n=50) patients and controls; 3) Provide clinical data and well characterized subjects for research on aging and neurodegenerative disease; and 4) Obtain biological samples for genomic and proteomic research, and contributing novel cohorts, including Chinese-American and FTLD patients, to the National Cell Repository for AD (NCRAD). All subjects will be evaluated using the UDS plus several neurological, cognitive, and personality measures specific to UCSF to better understand the heterogeneity of and overlap between dementias, improve our ability to capture the very earliest signs of neurodegeneration, study the transition from normal aging to MCI, and facilitate interventions. RELEVANCE (See instructions): The prevalence of dementing disorders will soon reach epidemic proportions in the United States. By recruiting and assessing a broad range of patients and elderly controls, the Clinical Core of this ADRC plays a central role in this ADRC's ability to promote the interventional, translational, and biological research in dementias necessary to develop new treatments and optimize patient care.